Your browser doesn't support javascript.
loading
A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms.
Fleming, Leah M; Javitt, Daniel C; Carter, Cameron S; Kantrowitz, Joshua T; Girgis, Ragy R; Kegeles, Lawrence S; Ragland, John D; Maddock, Richard J; Lesh, Tyler A; Tanase, Costin; Robinson, James; Potter, William Z; Carlson, Marlene; Wall, Melanie M; Choo, Tse-Hwei; Grinband, Jack; Lieberman, Jeffrey; Krystal, John H; Corlett, Philip R.
Afiliação
  • Fleming LM; Department of Psychiatry, Yale University, New Haven, CT, United States of America; Interdepartmental Neuroscience Program, Yale University, New Haven, CT, United States of America.
  • Javitt DC; Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, United States of America; Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, NY, United States of America.
  • Carter CS; Department of Psychiatry, University of California, Davis, United States of America.
  • Kantrowitz JT; Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, United States of America; Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, NY, United States of America.
  • Girgis RR; Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, United States of America.
  • Kegeles LS; Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, United States of America.
  • Ragland JD; Department of Psychiatry, University of California, Davis, United States of America.
  • Maddock RJ; Department of Psychiatry, University of California, Davis, United States of America.
  • Lesh TA; Department of Psychiatry, University of California, Davis, United States of America.
  • Tanase C; Department of Psychiatry, University of California, Davis, United States of America.
  • Robinson J; Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, NY, United States of America.
  • Potter WZ; National Institute of Mental Health, Rockville, MD, United States of America.
  • Carlson M; Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, United States of America.
  • Wall MM; Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, United States of America; National Institute of Mental Health, Rockville, MD, United States of America.
  • Choo TH; Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, United States of America.
  • Grinband J; Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, United States of America.
  • Lieberman J; Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, United States of America.
  • Krystal JH; Department of Psychiatry, Yale University, New Haven, CT, United States of America.
  • Corlett PR; Department of Psychiatry, Yale University, New Haven, CT, United States of America. Electronic address: philip.corlett@yale.edu.
Neuroimage Clin ; 22: 101739, 2019.
Article em En | MEDLINE | ID: mdl-30852397
Ketamine is an uncompetitive N-methyl-d-aspartate (NMDA) glutamate receptor antagonist. It induces effects in healthy individuals that mimic symptoms associated with schizophrenia. We sought to root these experiences in altered brain function, specifically aberrant resting state functional connectivity (rsfMRI). In the present study, we acquired rsfMRI data under ketamine and placebo in a between-subjects design and analyzed seed-based measures of rsfMRI using large-scale networks, dorsolateral prefrontal cortex (DLPFC) and sub-nuclei of the thalamus. We found ketamine-induced alterations in rsfMRI connectivity similar to those seen in patients with schizophrenia, some changes that may be more comparable to early stages of schizophrenia, and other connectivity signatures seen in patients that ketamine did not recreate. We do not find any circuits from our regions of interest that correlates with positive symptoms of schizophrenia in our sample, although we find that DLPFC connectivity with ACC does correlate with a mood measure. These results provide support for ketamine's use as a model of certain biomarkers of schizophrenia, particularly for early or at-risk patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esquizofrenia / Encéfalo / Antagonistas de Aminoácidos Excitatórios / Ketamina / Rede Nervosa Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Neuroimage Clin Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esquizofrenia / Encéfalo / Antagonistas de Aminoácidos Excitatórios / Ketamina / Rede Nervosa Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Neuroimage Clin Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos